Header Images

Private Sector Innovation Relationships

Selah Genomics

News Release: Selah Genomics (formerly Lab21) and ITOR unveil major leap forward in personalized cancer medicine with next-generation gene-sequencing technology

ITOR has formed a formal collaborative relationship with Selah Genomics (formerly Lab 21) with the shared objective of developing a true center of excellence in cancer care in Greenville.

Selah Genomics is a healthcare diagnostics company that provides advanced testing services to healthcare providers and the pharmaceutical and biotechnology industries, with oncology being a major emphasis area. Selah Genomics' oncology service areas include:

  1. Colorectal Cancer
  2. Lung Cancer
  3. Breast Cancer
  4. Skin Cancer
  5. Prostate Cancer
  6. Other - including a molecular profiling test to help determine the primary cancer in Cancer of Unknown Primary (CUP)

Selah Genomics has full development capability from IP or early technology through full development cycle, regulatory approval, manufacture and global commercialization.

The ITOR-Selah Genomics relationship is focused on cancer management and clinical testing - which combines the unique clinical expertise provided by ITOR and the surrounding area's existing oncology services, together with the diagnostic services and product experiences offered by Selah Genomics. The goal will be to achieve multiple functions to support molecular diagnostic technologies in personalized medicine and local clinical trial & pre-clinical initiatives within the oncology area, including the potential development of proprietary and novel assays. Ultimately, pharmaceutical companies will be able to avail themselves of a "complete package" at one site in Greenville: Clinical management, logistics handling, and comprehensive diagnostic services.



ITOR's Biorepository Services Platform and KIYATEC are actively exploring mutually beneficial translational research initiatives and opportunities in the field of oncology.

KIYATEC is a life sciences & biotechnology company commercializing innovative three-dimensional (3D) cell culture plasticware and cell-based diagnostics for use in the healthcare, pharmaceutical, and life sciences industries.

By combining the best aspects of traditional 2D cell culture with the enormous scientific benefits of culturing cells in 3D, KIYATEC helps researchers better understand and predict complex behavior of cell and tissue systems in vitro - thereby providing a more accurate simulation of phenomena within the human body which allows for improved pharmaceutical research and testing, more precise diagnostic methods, and more personalized treatment planning.

Established in 2005 and based in Upstate South Carolina, KIYATEC evolved from research at Clemson University's Bioengineering Department. The firm is continuing to expand the utility of 3D cell culture technology to further enable research, diagnostic, and treatment advancements.



NUBAD LLC is a drug discovery company devoted to the development of novel therapeutics that target nucleic acids (DNA and RNA).

Founded in 2009 using technologies developed in Clemson University's Department of Chemistry, NUBAD's efforts are centered around developing tools for drug discovery as well as developing small molecule drug libraries for screening and target validation.

NUBAD's approach to nucleic acid targeted drugs and probes is complimentary to the goals of personalized medicine set by ITOR and GHS teams. An example of such synergy is the development of inhibitors of DNA-transcription factor interactions as anticancer drugs.